Clinical Trial Search

Primary: Progression-Free Survival (PFS) - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months — 58.2; 28.9 percentage of participants

Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants

Primary: Action Research Arm Test — 4.1 units on a scale

Primary: Incidence of Severe Toxicities — 20 percentage of participants

Primary: Overall Survival (OS) - Stratified Analysis, Randomized Portion — 12.7; 9.7 months — p=0.2872

Primary: Percentage of Participants Who Experience Each Treatment Emergent Adverse Event Experienced by ≥5% of Participants During the 8-week Healing Treatment Period — 6.5; 6.5…

Primary: Clinically Significant Treatment Emergent Events — 37; 30; 22; 20 Number of patients

Primary: Mean Change in Visual Acuity — 15.0; 5.6 letters — p=0.02

Primary: Geometric Mean Concentrations (GMC) for Diphtheria and Tetanus Antigens — 9.3; 9.8; 9.4; 10.3 IU/mL

Primary: The Maximum Tolerated Dose (MTD) of 2 Schedules of BI 811283 in Combination With Cytarabine. — 100; NA mg

Primary: Patient-Reported Outcomes Measurement System Scale, a Scale Developed by the National Institute of Health to Assess Outcomes Across Different Trials. — 8.90; 12.26…

Primary: The Pharmacokinetic Profile of Darbe After the First Dose During Cooling — 180,866; 26,555 AUC (h*mU/L) — p=0.006

Primary: Pathologic Complete Response Rate (pCR) — 33 participants

Primary: Tumour Response Rate — 12.9; 31.1; 21.7; 50 Percentage of participants

Primary: Progression-free Survival (PFS) > 6 Months — 4.3 percentage of participants